<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513357</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0901</org_study_id>
    <nct_id>NCT00513357</nct_id>
  </id_info>
  <brief_title>Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients</brief_title>
  <official_title>A Randomized Clinical Trial of Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to evaluate the effectiveness of melatonin for
      the management of poor appetite and weight loss in advanced cancer patients. The
      effectiveness of melatonin on weight gain, keeping/gaining of lean muscle mass, improved
      appetite, and side effects will also be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melatonin is a hormone that is made by the part of the brain called the pineal gland and may
      help in letting your body know when it is time to go to sleep and when it is time to wake up.
      The researchers feel melatonin might help to improve your appetite, improve your overall
      sense of well-being, and maintain your current weight.

      If you are found to be eligible to take part in this study, you will see a nutritionist at
      the first (baseline) visit. The nutritionist will measure the amount of calories you consume.
      You will be asked to report all food and drinks you have had in a 3-day period. If you are
      unable to remember what you have eaten and drunk in the last 3 days, you will be asked by the
      nutritionist to list all the food and drinks you have had within the last 24 hours.

      Your arm muscle diameter and your skin fold below your shoulder blade will be measured on the
      arm you don't normally use to write with. This is to determine your body fat, lean mass and
      water content of your body.

      Your resting energy expenditure will be measured. You will be asked to wear a breathing mask
      and to blow into a tube. This will allow your breath to be analyzed, to measure how many
      calories your body is using while you are at rest.

      Blood (about 1-2 tablespoons) will be drawn for tests to make sure there are no other
      treatable causes for your weight loss.

      This blood test may not need to be repeated if you have had a blood test in the last 3
      months.

      If you are found to be eligible to take part in this study, you will be randomly assigned (as
      in the toss of a coin) to one of 2 groups. Participants in Group 1 will take melatonin daily
      before bedtime for 4 weeks. Patients in Group 2 will take a placebo daily before bedtime for
      4 weeks. A placebo is a substance that looks like the study drug but which has no active
      ingredients. You will have an equal chance (50/50) of being placed in either group. Neither
      you nor any of the medical staff or researchers on this study will know if you are receiving
      the study drug or placebo.

      On Week 2, you will return to the clinic and you will repeat all the tests done at the
      baseline visit. If you are unable to return to M. D. Anderson to complete the evaluations on
      Day 14 (± 2 days), the research nurse will contact you by telephone and ask you about any
      side effects you are experiencing.

      At Week 4, you will return to the clinic and all the tests done at baseline will be repeated.

      At the end of 4 weeks, all study patients in both groups will be given the opportunity to
      take melatonin before going to sleep at night for an additional 4 weeks. If you choose not to
      continue on melatonin for an additional 4 weeks, you will be taken off study and blood will
      be drawn for your end of study tests which include albumin, C-reactive protein (CRP), thyroid
      stimulating hormone (TSH), vitamin B-12, and cortisol. These tests will require about 1-2
      tablespoons of blood to be drawn. If you choose to continue on melatonin for an additional 4
      weeks, you will be asked to return to the outpatient clinic at Week 6 to repeat the tests
      done at baseline.

      Your end of study tests will be done at the end of 8 weeks.

      You will continue to visit the study doctor at the outpatient clinic as long he feels it is
      necessary. At these visits, your height and weight will be recorded and you will be asked
      what food and drinks you have had.

      This is an investigational study. Melatonin is not currently approved by the FDA except to
      treat blind people with no light perception for sleep disorders-and is considered a
      food/nutritional supplement. Up to 126 patients will be enrolled at MD Anderson and at Duke
      University Medical Center in Durham, North Carolina.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Appetite as Measured by ESAS</measure>
    <time_frame>Baseline and at 4 weeks</time_frame>
    <description>Difference in ESAS (Edmonton Symptom Assessment Scale) assessment scores of appetite (symptom) from baseline evaluation [± 3 days] to 4 week evaluation [± 3 days], where the severity at the time of assessment is rated from 0 to 10 on a numerical scale; with 0 meaning that the symptom is absent and 10 that it is the worst possible severity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg of Melatonin before going to sleep at night for a period of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 mg of Placebo before going to sleep at night for a period of 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>20 mg by mouth daily for 4 Weeks</description>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule by mouth daily for 4 Weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with solid gastrointestinal tumors or lung cancer patients referred to
             palliative care and a 5% or more involuntary weight loss within the last 6 months with
             anorexia (&gt;3 on visual analog scale such as ESAS)

          2. Greater than or equal to 18 years of age

          3. Karnofsky score of 40 or higher

          4. Patient has the ability to maintain oral food intake during the study period

          5. If patients who have persistent anorexia/cachexia and are currently taking Megace,
             corticosteroids, non-steroidal anti-inflammatories (NSAID's), or thalidomide, they
             should be on the medication at least 2 weeks prior to study inclusion

          6. Ability to sign informed consent and understand study procedures

          7. Patient can continue all medications including complementary therapies or
             antineoplastic therapy while on-study other than melatonin if they have been on stable
             dose for at least 2 weeks

          8. Negative pregnancy testing in women with child bearing potential defined as not
             post-menopausal for 12 months or no previous surgical sterilization.

          9. Patients who cannot take Megace because of past history or elevated risk of DVT,
             adrenal insufficiency, impotence, hyperglycemia, CHF, menorrhagia, etc.

         10. Patients who have persistent anorexia/cachexia after treatment with Megace has failed

        Exclusion Criteria:

          1. Patients who have dementia or delirium on entry into study as determined by the
             palliative care specialist using DSM-IV-criteria

          2. Patients who are currently taking melatonin

          3. Inability to take oral food during the study period

          4. Unstable secondary cachexia caused by nausea, diarrhea, taste abnormalities,
             mucositis, constipation, dysphagia, or clinical depression prior to study inclusion.
             These symptoms should be resolved or stable for &gt;/= 2 weeks at the time of inclusion
             into study as determined by the Palliative Care Specialist.

          5. Inability to sign informed consent or understand study procedures

          6. Karnofsky score of &lt; 40

          7. Patients &lt; 18 years of age

          8. Patients with &lt;/= 5% involuntary weight loss within the last 6 months and anorexia of
             &lt; 3 on ESAS

          9. Patients who are on complementary therapies containing melatonin or on medications for
             &lt; 2 weeks and not on stable dose

         10. Patients who have a cortisol level of &lt;/= 4.3 mg/dL at baseline will be excluded,
             unless they are on replacement corticosteroids.

         11. Patients with a TSH of &lt;/= 0.50 or &gt;/= 10 mcL/mL at baseline will be excluded

         12. Pregnant females or females who are lactating/nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rony Dev, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joan Karnell Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <results_first_submitted>June 6, 2012</results_first_submitted>
  <results_first_submitted_qc>August 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2012</results_first_posted>
  <last_update_submitted>December 7, 2012</last_update_submitted>
  <last_update_submitted_qc>December 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Cachexia</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Placebo</keyword>
  <keyword>Anorexia</keyword>
  <keyword>Weight Loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 07/21/2006 -04/08/2011. All participants recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 125 participants, there were 52 participants excluded (43 did not meet inclusion criteria; and 9 declined to participate).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Melatonin</title>
          <description>20 mg of Melatonin before going to sleep at night for a period of 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>20 mg of placebo before going to sleep at night for a period of 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>did not receive allocated placebo</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Melatonin</title>
          <description>20 mg of Melatonin before going to sleep at night for a period of 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>20 mg of placebo before going to sleep at night for a period of 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age range</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="36" upper_limit="76"/>
                    <measurement group_id="B2" value="62" lower_limit="32" upper_limit="86"/>
                    <measurement group_id="B3" value="59" lower_limit="32" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Appetite as Measured by ESAS</title>
        <description>Difference in ESAS (Edmonton Symptom Assessment Scale) assessment scores of appetite (symptom) from baseline evaluation [± 3 days] to 4 week evaluation [± 3 days], where the severity at the time of assessment is rated from 0 to 10 on a numerical scale; with 0 meaning that the symptom is absent and 10 that it is the worst possible severity.</description>
        <time_frame>Baseline and at 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>20 mg of Melatonin before going to sleep at night for a period of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>20 mg of placebo before going to sleep at night for a period of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Appetite as Measured by ESAS</title>
          <description>Difference in ESAS (Edmonton Symptom Assessment Scale) assessment scores of appetite (symptom) from baseline evaluation [± 3 days] to 4 week evaluation [± 3 days], where the severity at the time of assessment is rated from 0 to 10 on a numerical scale; with 0 meaning that the symptom is absent and 10 that it is the worst possible severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="2.6" lower_limit="6" upper_limit="8"/>
                    <measurement group_id="O2" value="-1.19" spread="2.3" lower_limit="4" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Melatonin</title>
          <description>20 mg of Melatonin before going to sleep at night for a period of 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>20 mg of placebo before going to sleep at night for a period of 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <description>Aspartate transaminase (AST), serum glutamic oxaloacetic transaminase (SGOT)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Abdomen</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Constitutional Symptom (other)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Syncope (Fainting)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Egidio Del Fabbro</name_or_title>
      <organization>University of Texas MD Anderson Cancer Center</organization>
      <phone>713-563-4157</phone>
      <email>ammarin@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

